After nearly seven months and two prior recalls, Viatris continues to be vexed by labeling issues on its biosimilar to Sanofi’s diabetes blockbuster Lantus.
Viatris’ Mylan this week said it was once again recalling a solo batch of insulin glargine injection over the potential for the label to be missing on some prefilled pens. Similar issues cropped up back in January and then again in April, with recalls following in both cases.
The batch covered under this week’s recall comprises 3-ml prefilled pens, which come in cartons of five, Viatris said in a release. The company emphasized that the market pull relates specifically to unbranded insulin glargine rather than Viatris’ branded Lantus biosim Semglee.
Viatris markets several versions of the diabetes medication. Both the unbranded and branded format, dubbed Semglee, boast interchangeability tags, which means they can be substituted for Sanofi’s med at the pharmacy counter.
